Positive impactSector
Mankind, Dr Reddy, Gland Pharma, others lift Nifty Pharma up over 1% as US exempts certain drugs from 100% tariffs
Upstox 2 hrs ago·29 Sept 2026, 5:16 am
The Indian pharmaceutical sector received a significant boost today as the United States announced an exemption from its proposed 100% tariffs for a specific list of generic drugs. This policy shift directly benefits major exporters like Gland Pharma, Dr. Reddy's, and Mankind Pharma, who have a substantial portion of their revenue tied to the American market. Consequently, the Nifty Pharma index surged by more than 1%, lifting the broader market sentiment.
For investors, this news is a positive development as it alleviates immediate trade uncertainty for these companies. It suggests that the US administration is prioritizing drug affordability and supply chain stability over aggressive tariff hikes. However, the exemption is limited to certain products, so investors should monitor the duration of this relief and watch for any further updates on trade negotiations.
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Gland Pharma (GLAND).
- Category: Sector.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Gland Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
